Alpha-Lipoic Acid — Research Profile

Regular ALA supplements contain a 50/50 racemic mix of R-lipoic acid and S-lipoic acid. R-lipoic acid is the naturally occurring form your body produces and uses — it is more biologically active and better absorbed. The S-form is a synthetic byproduct that may actually compete with and reduce R-ALA's effectiveness. For optimal results, choose R-ALA or stabilized Na-R-ALA.

Yes. Multiple clinical trials show ALA improves insulin sensitivity and lowers fasting blood glucose ^[2]. A 2011 trial found 300mg daily reduced fasting glucose and HbA1c in type 2 diabetes patients. However, this blood-sugar-lowering effect means you must monitor glucose carefully if taking diabetes medications, as the combined effect could cause hypoglycemia.

Food significantly reduces ALA absorption — bioavailability drops by approximately 30-40% when taken with meals. For maximum benefit, take ALA 30 minutes before eating. If GI side effects are an issue, taking it with a small amount of food is an acceptable compromise.

The R-enantiomer is the biologically active form the body also produces, and its peak plasma levels run 40 to 50 percent higher than the S-form, making R-ALA or sodium-R-lipoate the more efficiently absorbed oral choice. That said, the large neuropathy and metabolic trials used oral racemic (R/S) ALA at 300 to 600 mg/day, so racemic remains solidly evidence-backed. Intravenous ALA is used in some clinical settings but is not relevant to routine over-the-counter supplementation.

The best-supported benefit is symptomatic relief of diabetic peripheral neuropathy: oral ALA reduced pain, burning, and numbness scores in a dose-dependent way across trials totaling more than 1,200 patients. It also modestly lowered fasting glucose and insulin resistance in type 2 diabetics, and improved sperm motility and morphology in men with idiopathic infertility over roughly 3 months. Evidence is weaker for weight and general metabolic health: a 2025 meta-analysis in overweight or obese adults without diabetes found no significant change in glucose, insulin resistance, or lipids.

ALA is not an essential nutrient, so there is no RDA and dosing is condition-specific. Diabetic neuropathy trials used 600 mg/day orally, the dose the SYDNEY 2 investigators judged optimal because higher amounts (1,200 to 1,800 mg) added side effects without more benefit. Metabolic and lipid studies used a wider 300 to 1,200 mg/day range, with glycemic benefit seen even at 300 mg/day over 8 weeks.

Take it on an empty stomach, because food lowers ALA absorption by about 20 percent and blunts its peak plasma level. Practically, that means taking it at least 2 hours after a meal, or at least 30 minutes before eating. No specific time of day has been shown to improve efficacy; the empty-stomach requirement is what leads most people to dose it first thing in the morning or before bed.

The most common side effects are gastrointestinal, chiefly nausea, vomiting, and vertigo, which increased with dose from 600 up to 1,800 mg/day in the SYDNEY 2 trial. The notable rare risk is insulin autoimmune syndrome causing spontaneous hypoglycemia, driven by ALA's sulfhydryl group and reported at 300 to 600 mg/day in people carrying certain HLA types (HLA-DRB1*0406 in East Asians, *0403 in Caucasians); it resolves after stopping the supplement. At 600 mg/day or below, most users tolerate ALA without significant problems.

The main concern is additive blood-glucose lowering: ALA reduces fasting glucose and insulin resistance, so combining it with insulin or oral antidiabetic drugs can push blood sugar too low and calls for glucose monitoring. This risk is compounded by ALA's documented ability to trigger autoimmune hypoglycemia in susceptible individuals. Direct interaction data with other drug classes are limited, so anyone on glucose-lowering medication should coordinate use with their prescriber.

The clearest candidates are people with symptomatic diabetic peripheral neuropathy, where oral ALA has the strongest evidence for reducing pain and numbness, and type 2 diabetics seeking modest support for glucose control and oxidative stress. Men with idiopathic infertility may benefit from improved sperm motility and morphology. It is less justified for general weight loss or metabolic health in people without diabetes, where benefits were not significant, and anyone prone to hypoglycemia or with a personal or family history of autoimmune conditions should be cautious given the insulin autoimmune syndrome risk.

Onset depends on the target. In the SYDNEY 2 trial, oral ALA measurably reduced diabetic neuropathy symptom scores (pain, burning, numbness) within about 5 weeks. For blood lipids, a meta-analysis found the effects on LDL and triglycerides were duration-dependent across trials lasting 2 to 16 weeks, so several weeks to a few months is a more realistic expectation for metabolic changes. Antioxidant marker shifts can occur sooner, but symptomatic benefit is not immediate.

Most controlled trials ran only 5 weeks to about 4 months, so safety of continuous use beyond a few months is not well established. The main documented risk with ongoing use is a rare insulin autoimmune syndrome (autoimmune hypoglycemia) tied to ALA's sulfhydryl group, reported at doses as low as 300 to 600 mg/day and reversible after stopping. At routine doses of 600 mg/day or less, ALA was otherwise well tolerated in these trials, with mostly mild gastrointestinal effects.

Yes. In the SYDNEY 2 trial, nausea, vomiting, and vertigo increased in a dose-dependent way as the dose rose from 600 to 1,800 mg/day, and the investigators concluded 600 mg gave the best benefit-to-side-effect ratio. Separately, even modest doses of 300 to 600 mg/day have triggered autoimmune hypoglycemia in genetically susceptible people. There is no established tolerable upper intake level, so going much above 600 mg/day without medical supervision adds side effects without clear added benefit.

ALA is commonly stacked with other antioxidants or glycemic-support supplements. A systematic review found it did not significantly change serum iron, ferritin, or total iron-binding capacity overall, so it is unlikely to interfere with iron status. Because ALA can lower fasting glucose and insulin resistance, pairing it with other blood-sugar-lowering supplements such as berberine, chromium, or cinnamon can produce additive effects worth watching. What matters most for absorption is separating ALA from a meal rather than which supplements accompany it.

Check the isomer. Most products are racemic (R/S) ALA, but the R-enantiomer reaches plasma concentrations 40 to 50 percent higher, so R-ALA or stabilized sodium-R-lipoate delivers more active compound per milligram. Confirm the labeled dose per capsule falls in the studied 300 to 600 mg range, and favor products meant for empty-stomach dosing, since taking ALA with food cuts absorption by about 20 percent. Third-party purity testing is worth prioritizing because ALA is chemically unstable and degrades with heat and moisture.